我们能否兑现“承诺”？AGO乳腺委员会：关于促性腺激素释放激素类似物保留卵巢功能的近期证据评论
Can We Keep the 'PROMISE'? AGO Breast Commission: Commentary on Recent Evidence Regarding LHRH Analogues for the Preservation of Ovarian Function.
作者信息
Loibl Sibylle, Fersis Nicos, Harbeck Nadia
出版信息
Breast Care (Basel). 2011 Dec;6(6):467-470. doi: 10.1159/000335477. Epub 2011 Dec 20.
Abstract
Recently reported data from the German ZORO trial and the Italian PROMISE-GIM6 trial have come to different conclusions. The AGO Breast Commission does not recommend the general use of luteinizing hormone-releasing hormone (LHRH) analogues for the preservation of ovarian function. Instead, we distinguish between patients with hormone receptor-negative and hormone receptor-positive disease. This article reviews the AGO recommendations in light of the ZORO and PROMISE-GIM6 data. In conclusion, separate recommendations are needed for the prevention of ovarian failure and for fertility preservation because the trials did not investigate fertility rate as a primary outcome measure. The results from not yet published trials such as OPTION and POEM may shed new light on the role of LHRH analogues.
摘要
最近德国ZORO试验和意大利PROMISE - GIM6试验报告的数据得出了不同结论。AGO乳腺委员会不建议普遍使用促黄体生成素释放激素（LHRH）类似物来保留卵巢功能。相反，我们区分激素受体阴性和激素受体阳性疾病的患者。本文根据ZORO和PROMISE - GIM6的数据回顾了AGO的建议。总之，预防卵巢功能衰竭和保留生育能力需要分别提出建议，因为这些试验并未将生育率作为主要结局指标进行研究。尚未发表的试验如OPTION和POEM的结果可能会为LHRH类似物的作用带来新的启示。
相似文献
1
Can We Keep the 'PROMISE'? AGO Breast Commission: Commentary on Recent Evidence Regarding LHRH Analogues for the Preservation of Ovarian Function.我们能否兑现“承诺”？AGO乳腺委员会：关于促性腺激素释放激素类似物保留卵巢功能的近期证据评论
Breast Care (Basel). 2011 Dec;6(6):467-470. doi: 10.1159/000335477. Epub 2011 Dec 20.
2
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.促黄体生成素释放激素激动剂和拮抗剂在妇科癌症中的应用。
Hum Reprod. 1994 Jul;9(7):1364-79. doi: 10.1093/oxfordjournals.humrep.a138714.
3
Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.化疗期间的卵巢临时抑制以保护乳腺癌患者的卵巢功能和生育能力：意大利肿瘤医学协会进行证据评估和推荐的 GRADE 方法。
Eur J Cancer. 2017 Jan;71:25-33. doi: 10.1016/j.ejca.2016.10.034. Epub 2016 Dec 9.
4
Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.使用AN-152的促黄体生成素释放激素受体靶向化疗。
Neuroendocrinology. 2009;90(1):15-8. doi: 10.1159/000225410. Epub 2009 Jun 12.
5
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.绝经前早期乳腺癌患者化疗中药物性卵巢抑制的长期结局。
J Natl Cancer Inst. 2022 Mar 8;114(3):400-408. doi: 10.1093/jnci/djab213.
6
Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.促性腺激素释放激素激动剂在早期乳腺癌化疗的绝经前妇女中保存卵巢功能的作用：系统评价和荟萃分析。
JAMA Oncol. 2016 Jan;2(1):65-73. doi: 10.1001/jamaoncol.2015.3251.
7
[The use of GnRH analogues in early and advanced breast carcinomas].[促性腺激素释放激素类似物在早期和晚期乳腺癌中的应用]
Gynecol Obstet Fertil. 2005 Nov;33(11):914-9. doi: 10.1016/j.gyobfe.2005.09.010. Epub 2005 Oct 24.
8
9
Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells.促黄体生成激素释放激素类似物对肿瘤细胞的生长抑制作用。
Trends Endocrinol Metab. 1997 Nov;8(9):355-62. doi: 10.1016/s1043-2760(97)00155-0.
10
Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.促黄体生成激素释放激素受体在人卵巢癌和子宫内膜癌中的表达：频率、自身调节以及与促黄体生成激素释放激素类似物直接抗增殖活性的相关性
Am J Obstet Gynecol. 2002 Feb;186(2):171-9. doi: 10.1067/mob.2002.119633.
本文引用的文献
1
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.促性腺激素释放激素激动剂曲普瑞林用于乳腺癌新辅助化疗中卵巢功能保护的随机试验。
J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9.
2
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.促性腺激素释放激素类似物曲普瑞林对乳腺癌绝经前妇女化疗诱导早绝经发生的影响：一项随机试验。
JAMA. 2011 Jul 20;306(3):269-76. doi: 10.1001/jama.2011.991.
3
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.黄体生成素释放激素激动剂对现代辅助乳腺癌化疗后卵巢功能的影响：GBG 37 ZORO 研究。
J Clin Oncol. 2011 Jun 10;29(17):2334-41. doi: 10.1200/JCO.2010.32.5704. Epub 2011 May 2.
4
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.NSABP B-30 试验中辅助治疗的淋巴结阳性乳腺癌女性的月经史和生活质量结局。
J Clin Oncol. 2011 Mar 20;29(9):1110-6. doi: 10.1200/JCO.2010.29.7689. Epub 2011 Feb 7.
5
Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.促性腺激素释放激素类似物联合治疗在性腺毒性化疗中保护卵巢功能的系统评价和荟萃分析。
Fertil Steril. 2011 Mar 1;95(3):906-14.e1-4. doi: 10.1016/j.fertnstert.2010.11.017. Epub 2010 Dec 10.
6
Use of hormonal protection for chemotherapy-induced gonadotoxicity.使用激素保护措施应对化疗引起的性腺毒性。
Clin Obstet Gynecol. 2010 Dec;53(4):740-52. doi: 10.1097/GRF.0b013e3181f96cb1.
7
Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.早期乳腺癌化疗后仍处于绝经前状态的女性的卵巢储备。
Fertil Steril. 2010 Jul;94(2):638-44. doi: 10.1016/j.fertnstert.2009.03.045. Epub 2009 May 5.
8
Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review.乳腺癌辅助化疗患者的生育力保存：系统评价。
Fertil Steril. 2010 Jun;94(1):138-43. doi: 10.1016/j.fertnstert.2009.02.055. Epub 2009 Apr 1.
9
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.辅助性戈舍瑞林与早期乳腺癌化疗患者的卵巢保留：一项随机试验的结果
Breast Cancer Res Treat. 2009 Oct;117(3):561-7. doi: 10.1007/s10549-009-0313-5. Epub 2009 Jan 20.
10
Risk of menopause during the first year after breast cancer diagnosis.乳腺癌诊断后第一年出现绝经的风险。
J Clin Oncol. 1999 Aug;17(8):2365-70. doi: 10.1200/JCO.1999.17.8.2365.
Zotero 插件